Impact of interstitial pneumonia on the survival and risk factors analysis of patients with hematological malignancy

Wei Liang Chen, Yu Tzu Tsao, Tsun Hou Chang, Tsu Yi Chao, Woei Yau Kao, Yeu Chin Chen, Ching Liang Ho

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background. The emergence of interstitial pneumonia (IP) in patients with hematological malignancy (HM) is becoming a challenging scenario in current practice. However, detailed characterization and investigation of outcomes and risk factors on survival have not been addressed. Methods. We conducted a retrospective study of 42,584 cancer patients covering the period between 1996 and 2008 using the institutional cancer registry system. Among 816 HM patients, 61 patients with IP were recognized. The clinical features, laboratory results, and histological types were studied to determine the impact of IP on survival and identify the profile of prognostic factors. Results. HM patients with IP showed a significant worse survival than those without IP in the 5-year overall survival (P=0.027). The overall survival showed no significant difference between infectious pneumonia and noninfectious interstitial pneumonia (IIP versus nIIP) (P=0.323). In a multivariate Cox regression model, leukocyte and platelet count were associated with increased risk of death. Conclusions. The occurrence of IP in HM patients is associated with increased mortality. Of interest, nIIP is a prognostic indicator in patients with lymphoma but not in patients with leukemia. However, aggressive management of IP in patients with HM is strongly advised, and further prospective survey is warranted.

Original languageEnglish
Article number185362
JournalBioMed Research International
Volume2013
DOIs
Publication statusPublished - 2013
Externally publishedYes

Fingerprint

Interstitial Lung Diseases
Hematologic Neoplasms
Factor analysis
Statistical Factor Analysis
Survival
Platelets
Platelet Count
Leukocyte Count
Proportional Hazards Models
Registries
Lymphoma
Neoplasms
Pneumonia
Leukemia
Retrospective Studies
Mortality

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)

Cite this

Impact of interstitial pneumonia on the survival and risk factors analysis of patients with hematological malignancy. / Chen, Wei Liang; Tsao, Yu Tzu; Chang, Tsun Hou; Chao, Tsu Yi; Kao, Woei Yau; Chen, Yeu Chin; Ho, Ching Liang.

In: BioMed Research International, Vol. 2013, 185362, 2013.

Research output: Contribution to journalArticle

Chen, Wei Liang ; Tsao, Yu Tzu ; Chang, Tsun Hou ; Chao, Tsu Yi ; Kao, Woei Yau ; Chen, Yeu Chin ; Ho, Ching Liang. / Impact of interstitial pneumonia on the survival and risk factors analysis of patients with hematological malignancy. In: BioMed Research International. 2013 ; Vol. 2013.
@article{8d6357992af948e7ac9789b143e5930d,
title = "Impact of interstitial pneumonia on the survival and risk factors analysis of patients with hematological malignancy",
abstract = "Background. The emergence of interstitial pneumonia (IP) in patients with hematological malignancy (HM) is becoming a challenging scenario in current practice. However, detailed characterization and investigation of outcomes and risk factors on survival have not been addressed. Methods. We conducted a retrospective study of 42,584 cancer patients covering the period between 1996 and 2008 using the institutional cancer registry system. Among 816 HM patients, 61 patients with IP were recognized. The clinical features, laboratory results, and histological types were studied to determine the impact of IP on survival and identify the profile of prognostic factors. Results. HM patients with IP showed a significant worse survival than those without IP in the 5-year overall survival (P=0.027). The overall survival showed no significant difference between infectious pneumonia and noninfectious interstitial pneumonia (IIP versus nIIP) (P=0.323). In a multivariate Cox regression model, leukocyte and platelet count were associated with increased risk of death. Conclusions. The occurrence of IP in HM patients is associated with increased mortality. Of interest, nIIP is a prognostic indicator in patients with lymphoma but not in patients with leukemia. However, aggressive management of IP in patients with HM is strongly advised, and further prospective survey is warranted.",
author = "Chen, {Wei Liang} and Tsao, {Yu Tzu} and Chang, {Tsun Hou} and Chao, {Tsu Yi} and Kao, {Woei Yau} and Chen, {Yeu Chin} and Ho, {Ching Liang}",
year = "2013",
doi = "10.1155/2013/185362",
language = "English",
volume = "2013",
journal = "BioMed Research International",
issn = "2314-6133",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Impact of interstitial pneumonia on the survival and risk factors analysis of patients with hematological malignancy

AU - Chen, Wei Liang

AU - Tsao, Yu Tzu

AU - Chang, Tsun Hou

AU - Chao, Tsu Yi

AU - Kao, Woei Yau

AU - Chen, Yeu Chin

AU - Ho, Ching Liang

PY - 2013

Y1 - 2013

N2 - Background. The emergence of interstitial pneumonia (IP) in patients with hematological malignancy (HM) is becoming a challenging scenario in current practice. However, detailed characterization and investigation of outcomes and risk factors on survival have not been addressed. Methods. We conducted a retrospective study of 42,584 cancer patients covering the period between 1996 and 2008 using the institutional cancer registry system. Among 816 HM patients, 61 patients with IP were recognized. The clinical features, laboratory results, and histological types were studied to determine the impact of IP on survival and identify the profile of prognostic factors. Results. HM patients with IP showed a significant worse survival than those without IP in the 5-year overall survival (P=0.027). The overall survival showed no significant difference between infectious pneumonia and noninfectious interstitial pneumonia (IIP versus nIIP) (P=0.323). In a multivariate Cox regression model, leukocyte and platelet count were associated with increased risk of death. Conclusions. The occurrence of IP in HM patients is associated with increased mortality. Of interest, nIIP is a prognostic indicator in patients with lymphoma but not in patients with leukemia. However, aggressive management of IP in patients with HM is strongly advised, and further prospective survey is warranted.

AB - Background. The emergence of interstitial pneumonia (IP) in patients with hematological malignancy (HM) is becoming a challenging scenario in current practice. However, detailed characterization and investigation of outcomes and risk factors on survival have not been addressed. Methods. We conducted a retrospective study of 42,584 cancer patients covering the period between 1996 and 2008 using the institutional cancer registry system. Among 816 HM patients, 61 patients with IP were recognized. The clinical features, laboratory results, and histological types were studied to determine the impact of IP on survival and identify the profile of prognostic factors. Results. HM patients with IP showed a significant worse survival than those without IP in the 5-year overall survival (P=0.027). The overall survival showed no significant difference between infectious pneumonia and noninfectious interstitial pneumonia (IIP versus nIIP) (P=0.323). In a multivariate Cox regression model, leukocyte and platelet count were associated with increased risk of death. Conclusions. The occurrence of IP in HM patients is associated with increased mortality. Of interest, nIIP is a prognostic indicator in patients with lymphoma but not in patients with leukemia. However, aggressive management of IP in patients with HM is strongly advised, and further prospective survey is warranted.

UR - http://www.scopus.com/inward/record.url?scp=84884882893&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884882893&partnerID=8YFLogxK

U2 - 10.1155/2013/185362

DO - 10.1155/2013/185362

M3 - Article

C2 - 24093091

AN - SCOPUS:84884882893

VL - 2013

JO - BioMed Research International

JF - BioMed Research International

SN - 2314-6133

M1 - 185362

ER -